Skip to main content
. 2012 Oct 24;122(11):3931–3942. doi: 10.1172/JCI63170

Figure 3. DCs-αGC-ATL313 administered before or after ischemia protect kidneys from moderate IRI.

Figure 3

(A) The experimental process was similar to that in Figure 2, except that WT mice were subjected to 28 minutes of moderate ischemia and 24 of hours reperfusion. Plasma creatinine was measured 24 hours after sham operation or IRI. n = 2–4. (B) The experiment was similar to that in A, except that mice were subjected to renal artery clamping (instead of renal pedicle clamping) for 35 minutes; plasma creatinine was measured after 24 hours of reperfusion. n = 4 and 5 for DCs-αGC and DCs-αGC-ATL313, respectively. (C) DCs-αGC-ATL313 were administered 1 or 6 hours after moderate (28 minutes) kidney ischemia, and plasma creatinine was measured after 24 or 48 hours of reperfusion (from the end of the ischemic period). n = 3–5. *P < 0.05; **P < 0.01; ***P < 0.001. Values are mean ± SEM.